#MEAwarenessHour
Wir brauchen Sofortmaßnahmen:
- Aufklärung gerade auch von Ärztis, MD, DRV...
- Förderung der anstehenden Studien zu #Inebilizumab und #Mitodicure
300mio. jährlich sind angemessen
Und nein, wir brauchen nicht "bessere Versorgung" sondern überhaupt Versorgung!
@bmg-bund.bsky.social
Finally also showing the results from the #MITIGATE study in #IgG4RD #igg4ward
#inebilizumab being approved by @fda.gov now for #IgG4RD !
The first ever @fda.gov approved treatment for IgG4-RD is upon us. #inebilizumab #uplizna @amgen.bsky.social
A much needed option for this very heterogenous and challenging disease which can literally affect any organ but prominently liver and bile ducts.
#liversky #gisky
The label for #inebilizumab #uplizna is very broad. Before starting:
✅ serum immunoglobulins & consult immunology if low
✅HBV status. Consult GI/Hep if HBsAg or HBcAb pos
✅TB status and consult ID if positive
✅ do not administer live or attenuated vaccines
#liversky #gisky
Summary of the @nejm.org paper which summarizes the RCT MITIGATE trial which led to the @fda.gov approval of #inebilizumab
#gisky #liversky
🆕 Visual Abstract with Healio Rheumatology 🟢
🔥 New Therapy for IgG4-Related Disease: INEBILIZUMAB
💉 RCT of inebilizumab (anti-CD19) vs placebo
👥 Adult pts with IgG4-RD involving ≥ 2 organs
📊 Results:⇣flare rate,⇡remission
#IgG4RD #RareDiseases #Rheumatology #Inebilizumab
Brilliant! Now I can share our study published @nejm.org on #IgG4-RD demonstrating the efficacy of #inebilizumab to prevent flare
N Engl J Med. 2024 Nov 14. doi: 10.1056/NEJMoa2409712. Online ahead of print.
ankommen, denen die Kassen bisher ja nicht einmal LDN oder Ivabradin zahlen.
———
How likely is it that the new kids on the block in B-cell depletion (namely #Inebilizumab and #Ocrelizumab, at €78,700 vs. €6,600) will make their way into the real world of #PAIS, when there
3/5
A picture of an infusion bottle of Rituximab. Photo seen on me-pedia.org
Für wie wahrscheinlich können wir es halten, dass die new kids on the block in der B-Zell-Depletion (namentlich #Inebilizumab und #Ocrelizumab, á 78700€ vs. 6600€) es jeweils in die real world of #PAIS schaffen, wenn es doch bereits seit langem einen generischen
1/5
#Inebilizumab-- anti-CD19 shown efficacious to reduce #IgG4RD flare rates in MITIGATE study. #ACR24 #YearInReview
